SALT LAKE CITY, March 8 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (www.myriad.com ) announced today that Jose Fojas has been appointed Vice President of Marketing for Myriad Pharmaceuticals, Inc.
Mr. Fojas will oversee all aspects of marketing therapeutic compounds at Myriad, including marketing plans, forecasts and pricing. Initially, he will refine and execute the marketing strategy for Myriad’s two lead drug candidates, Flurizan(TM), for the treatment of Alzheimer’s disease and MPC-6827 for the treatment of metastatic brain tumors. Mr. Fojas will also initiate plans for the Company’s blood cancer drug candidate and its two compounds that are scheduled for Investigational New Drug application this calendar year for AIDS and thrombosis.
Mr. Fojas was previously with Eisai, Inc., where he served as Group Franchise Director for the Critical Care and Oncology Groups of the $2 Billion United States arm of Eisai Co., Ltd., a USD$4.3 Billion global operation with headquarters in Japan. In his eight years with Eisai, Mr. Fojas served in various marketing and sales management positions, including management of drugs in the Alzheimer’s disease, oncology, acute care and epilepsy markets. Prior to Eisai, Mr. Fojas managed products in the Oncology field for Schein Pharmaceutical and Purdue Frederick. Mr. Fojas received his Bachelor’s degree in Zoology from Miami University of Oxford, Ohio.
“It is with a great deal of pleasure that I welcome Jose to Myriad,” said Wayne Laslie, Chief Commercial Officer and Chief Operations Officer of Myriad Pharmaceuticals, Inc. “His strong marketing experience in areas of direct and immediate relevance to Myriad, includes a background well-suited to maximizing the potential of our full pipeline of drug candidates as we move them toward commercialization.”
Myriad Genetics, Inc. is a biopharmaceutical company focused on the development and marketing of novel healthcare products. The Company develops and markets predictive medicine products, and is developing and intends to market therapeutic products. Myriad’s news and other information are available on the Company’s Web site at www.myriad.com.
Flurizan is a trademark of Myriad Genetics, Inc. in the United States and other countries. All other trademarks mentioned are the property of their respective owners.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include the scheduling of two compounds for Investigational New Drug application this year. These forward-looking statements are based on management’s current expectation and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements. These include, but are not limited to, uncertainties as to the extent of future government regulation of Myriad Genetics’ business; uncertainties as to whether Myriad Genetics and its collaborators will be successful in developing, and obtaining regulatory approval for, and commercial acceptance of, therapeutic compounds; the risk that markets will not exist for therapeutic compounds that Myriad Genetics develops or if such markets exist, that Myriad Genetics will not be able to sell compounds, which it develops, at acceptable prices; and the risk that the Company will not be able to sustain revenue growth for its predictive medicine business and products. These and other risks are identified in the Company’s filings with the Securities and Exchange Commission, including the Company’s current Report on Form 8-K filed October 28, 2005. All information in this press release is as of March 8, 2006 and Myriad undertakes no duty to update this information unless required by law.
Myriad Genetics, Inc.
CONTACT: William A. Hockett, EVP, Communications of Myriad Genetics, Inc.,+1-801-584-3600, bhockett@myriad.com
Web site: http://www.myriad.com/
